Supernus Pharmaceuticals (SUPN) EBT (2011 - 2025)

Supernus Pharmaceuticals (SUPN) has 15 years of EBT data on file, last reported at -$1.9 million in Q4 2025.

• On a quarterly basis, EBT fell 107.25% year-over-year to -$1.9 million in Q4 2025; TTM through Dec 2025 was -$49.0 million, a 150.1% decrease from a year earlier, with the FY2025 full-year figure at -$49.0 million, down 150.1% from the prior year.
• EBT for Q4 2025 stood at -$1.9 million, up from -$58.0 million in the prior quarter.
• Over the last five years, EBT for SUPN reached as high as $44.9 million in Q3 2024 and fell as low as -$58.0 million in Q3 2025.
• Historically, EBT has averaged $9.3 million across 5 years, with a median of $10.4 million in 2021.
• Across the five-year window, EBT soared 2564.85% in 2024 and tumbled 2499.59% in 2025, its largest moves.
• Year by year, EBT stood at $2.1 million in 2021, then jumped by 1613.31% to $35.1 million in 2022, then sank by 97.18% to $990000.0 in 2023, then surged by 2564.85% to $26.4 million in 2024, then plunged by 107.25% to -$1.9 million in 2025.
• Per Business Quant data, the three most recent EBT figures were -$1.9 million in Q4 2025, -$58.0 million in Q3 2025, and $16.7 million in Q2 2025.